Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial - Wikidata - awgldk - TriplyDB

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial

http://www.wikidata.org/entity/Q35623623

about

Associations Between Hyperuricemia and Chronic Kidney Disease: A Review Uric acid and chronic kidney disease: which is chasing which?Stop chronic kidney disease progression: Time is approaching Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.Comorbidities in patients with crystal diseases and hyperuricemia.Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review.The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.Serum Uric Acid Level Predicts Progression of IgA Nephropathy in Females but Not in Males.EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy Uric acid as a target of therapy in CKD.Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome.A Randomized Controlled Trial of the Effects of Febuxostat Therapy on Adipokines and Markers of Kidney Fibrosis in Asymptomatic Hyperuricemic Patients With Diabetic Nephropathy.The role of fructose transporters in diseases linked to excessive fructose intake.Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.Urate reduction and renal preservation: what is the evidence?Hyperuricemia and chronic kidney disease: an enigma yet to be solved.Management of Gout and Hyperuricemia in CKD.Time to target uric acid to retard CKD progression.Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.Mendelian randomization analysis indicates serum urate has a causal effect on renal function in Chinese women.Treatment of asymptomatic hyperuricemia in chronic kidney disease: A new target in an old enemy - A review.Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.Hyperuricemia is associated with progression of IgA nephropathy.Significance of hyperuricemia in immunoglobulin A nephropathy.Differences in acute metabolism of fructose between hemodialysis patients and healthy subjects.High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy.Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis.Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article.Dopamine-Induced Changes in Serum Erythropoietin and Creatinine Clearance Reflect Risk Factors for Progression of IgA Nephropathy.

P2860

Q26796333-4E077744-D50B-4CDD-A065-0927C4651270 Q26824554-D4FCA7D2-BE76-4B11-A4EA-48BD4D4884E7 Q28078020-7DAC6472-2B99-4FA1-958A-9DF71E1141F1 Q33611859-9CF377E9-0FD2-4C97-AC40-AE1F0B217BC7 Q33706623-36327247-C1AB-49A9-96DA-2B9B8574DB37 Q33779697-8A0AD399-328B-4A0C-A737-E4E85013E8F9 Q33802797-E64C2F90-ECCA-40F8-A3F5-BE07F49AB9C9 Q34157725-E1E24B5A-84C0-46A4-BEA5-39DF46BA91D7 Q34682703-74359D6A-2961-4B19-9469-083F3E5603F4 Q34877729-BC62FACA-9BBA-449F-8C7A-91F9D96036C5 Q35128270-854B81DE-9A20-44D1-B5C1-9654887342C6 Q35605560-97CFA53D-99A2-4921-B4D4-F67E4E75E207 Q36113184-461FAE08-5ED0-429C-B5D5-DE11FAD4A014 Q36223297-468129FA-F4B4-420E-AD88-FE0B19D54278 Q36255567-2F93ED54-C7D5-49B6-B6F3-DAFE9390BD45 Q36373688-4868FCAB-25FB-4174-9C6D-649329A4F0CF Q36476464-66D7FBA6-D734-4F90-B8B4-2725941CEAE5 Q36801587-AF385724-7397-4E15-92FF-9DBD37948160 Q37447055-4C2159B3-6B9D-4877-85D2-43603DE1D94A Q37674565-9CCC364E-DBCD-4148-9624-66FC7AB56542 Q38058076-0107F3F7-5915-40DB-83A3-D191C18C53A0 Q38138322-11969B5A-D68E-4D3B-9C26-B80426958B86 Q38160768-D5212873-6044-4498-85CF-9C6EC6E58CDB Q38238942-14A8ED92-9DFE-446D-BCD0-C9239B00AD0E Q38812962-8DC2EEBC-1D4F-44AD-8F12-B6D8219EB2DB Q38848997-C0F41FE0-C5B3-4BA4-A204-8FC35C60D32F Q38970541-14873B59-E664-40C6-B80B-D95864D6D489 Q40063835-37764067-32D1-44A7-9A4D-537A0CEFCC8D Q41026351-479FED7A-846A-499D-AFB4-355CBD920A48 Q41026359-77956DB2-BD02-4FCF-B825-34635F6B6B51 Q41243378-FF3176EA-0624-45B8-B7AB-04B9EDE28148 Q41831220-A0216C03-04D7-45F9-B9ED-1564362A047F Q42278021-CEB6DDEE-90A4-46FA-86AE-D3585C70EFA3 Q43945608-06C1ADA0-6EBE-46DC-BB62-2AF6F57E88DF Q44441047-E394A158-451B-4607-88B9-11108D29BF92 Q47138528-F93DCB25-1673-46D2-AFC0-ED087B21BB49 Q47169238-C6047A71-4B2B-47F5-8483-4345DDE8BC62 Q47690427-3ABE6004-2C1C-45B8-AF35-26EB3AD4221F Q52622926-E7991B9A-840E-4778-BC0D-EC747E1AB780 Q53455993-44908506-6A30-491A-831D-95E49A6990FC

P2860

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial

http://www.wikidata.org/entity/Q35623623

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Clinical outcome of hyperurice ...... nd randomized controlled trial

@ast

Clinical outcome of hyperurice ...... nd randomized controlled trial

@en

type

label

Clinical outcome of hyperurice ...... nd randomized controlled trial

@ast

Clinical outcome of hyperurice ...... nd randomized controlled trial

@en

prefLabel

Clinical outcome of hyperurice ...... nd randomized controlled trial

@ast

Clinical outcome of hyperurice ...... nd randomized controlled trial

@en

P1433

Q35623623-38BC943C-CD84-44E1-9061-EBFFE734AE61

P1476

Q35623623-5906C802-F2C3-40BF-B43B-141B7BAC7845

P2093

Q35623623-0EB90794-02E8-4C79-8013-5A46EE158A9B

Q35623623-195297B0-3F8C-40E1-9E0C-4D7E08C2AEB3

Q35623623-267524B5-E86D-42CA-8DFA-B430BF6F47E1

Q35623623-386FD9F5-5683-43AE-8585-8DED668899A0

Q35623623-54D3EC9C-C586-4421-A42B-AD1C6033DD90

Q35623623-7B084499-3AE3-4007-8F0D-E6965CB96D0F

Q35623623-B13F0497-0403-4EA1-ADFA-99DE6C66A940

Q35623623-B89AA908-83B4-4733-90DE-DB02ECD390C2

Q35623623-BB7FDE79-9860-4F63-9472-26BD613170B2

P2860

Q35623623-07278021-2333-426F-9A55-552333C6C0D7

Q35623623-1DA63728-0FAE-49FA-890E-6B4B452F9756

Q35623623-414FB51A-4219-46D2-87A0-DA167F9BD3EA

Q35623623-512B3F05-1575-4A8C-90A0-6C9EA0A4FEDD

Q35623623-5BC6126E-E706-460C-9B27-30F758E33C3F

Q35623623-69D55415-955B-4D86-90FB-1649BC8B51DC

Q35623623-6E9D5D43-2DD3-4C7A-8EDF-CAD3B919DE02

Q35623623-79E3C9D5-4720-4D1B-83D5-CE4B0E4807A6

Q35623623-7FCFF36F-CA6F-4A7C-868E-93EBC3AB2C12

Q35623623-92F3FDF6-6B31-45A2-91BD-71284F87B9F5

P304

Q35623623-EFA48CCC-E4ED-4E2B-94F6-DA65CB5DF1E0

P31

Q35623623-65866584-478C-4F0A-8B8A-494F32EFBE4B

P356

Q35623623-EF2E2D5E-590B-4B70-BFEC-EE75B2316D07

P433

Q35623623-D8FED487-AF98-44EF-8DE8-913DCE43D272

P478

Q35623623-68C09641-F19D-4132-ADF6-670304385F0E

P577

Q35623623-DDC3094A-5727-4639-8E3F-36C6A96E81C9

P5875

Q35623623-1BD3F4E9-0E55-435F-9CBB-5D37B4AA6DD0

P698

Q35623623-F32AE5EE-740D-4F13-AC44-7149FA6312A2

P932

Q35623623-B8ED649C-B72E-436E-B175-38DCEE8CC410

P356

P1433

Kidney and Blood Pressure Research

P1476

Clinical outcome of hyperurice ...... nd randomized controlled trial

@en

P2093

Diana Jalal

http://www.w3.org/2001/XMLSchema#string

Haiping Mao

http://www.w3.org/2001/XMLSchema#string

Qiongqiong Yang

http://www.w3.org/2001/XMLSchema#string

Richard J Johnson

http://www.w3.org/2001/XMLSchema#string

Wei Chen

http://www.w3.org/2001/XMLSchema#string

Wenfang Chen

http://www.w3.org/2001/XMLSchema#string

Xueqing Yu

http://www.w3.org/2001/XMLSchema#string

Yongjun Shi

http://www.w3.org/2001/XMLSchema#string

Zhibin Li

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells.

Predicting renal outcome in IgA nephropathy.

Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells.

Inactivation of nitric oxide by uric acid.

Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress.

Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

Mild hyperuricemia induces glomerular hypertension in normal rats.

A role for uric acid in the progression of renal disease.

P304

153-160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000331453

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232479827

http://www.w3.org/2001/XMLSchema#string

P698

22116196

http://www.w3.org/2001/XMLSchema#string

P932

3242707

http://www.w3.org/2001/XMLSchema#string